Los Angeles, CANCT07739966Now EnrollingIRB Ready

Solid Tumor Clinical Trial in Los Angeles, CA

Access cutting-edge solid tumor treatment through this phase 1/2 clinical trial at a research site in Los Angeles. Study-provided care at no cost to qualified participants.

Sponsored by Daiichi Sankyo

Quick Self-Assessment

See if you qualify for this Los Angeles location

Preparing your pre-screening questions…

Expert Care in Los Angeles

Access solid tumor specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related solid tumor treatment provided free

Apply for This Los Angeles Location

Check if you qualify for this solid tumor clinical trial in Los Angeles, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Los Angeles

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Los Angeles site if eligible
  4. 4Begin participation

About This Solid Tumor Study in Los Angeles

The primary purpose of the study is to evaluate the safety, tolerability, and efficacy of DS-3939a in combination with other anticancer agents or as a monotherapy in participants with solid tumors.

Sponsor: Daiichi Sankyo

Who Can Participate

Inclusion Criteria

Sign and date the Main Trial informed consent form (ICF), prior to the start of any trial-specific procedures.
Adults greater than or equal to (≥)18 years of age at the time the Main Trial ICF is signed (follow local regulatory requirements if the legal age of consent for trial participation is \>18 years old).
Histologically documented Stage IIIB, IIIC disease who is not candidate for surgical resection or definitive chemoradiation, or Stage IV NSQ NSCLC.
Has a left ventricular ejection fraction (LVEF) ≥50 percent (%) by either an echocardiogram (ECHO) or multigated acquisition scan (MUGA) within 28 days of the first trial intervention.
Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 assessed no more than 14 days prior to initiation of trial interventions.
Has adequate organ function.
Participants must have measurable disease by investigator assessment according to RECIST v1.1. Additional Inclusion Criteria for Substudy 1: 1\. Participants must not have received prior systemic therapy for locally advanced unresectable or metastatic NSCLC. Additional Inclusion Criteria for Substudy 2:
Participants with AGA (excluding EGFR mutation): Participants have been previously treated with targeted therapy for the AGA and platinum-based chemotherapy for the advanced disease setting.
Participants without AGA: Participants have been previously treated with platinum-based chemotherapy and anti-programmed death-1 (anti-PD-1)/programmed death-ligand 1 (PD-L1) antibody
Part 2 only: Participants must have received only 1 or 2 prior lines of anticancer therapy for the advanced disease setting.

Exclusion Criteria

Prior systemic anticancer therapy targeting MUC1 or TA-MUC1.
Prior systemic anticancer therapy with topoisomerase 1 inhibitor or topoisomerase 1 inhibitor-based antibody-drug conjugate (ADCs) (e.g., datopotamab deruxtexan and Sacituzumab govitecan).
Has spinal cord compression or clinically active central nervous system (CNS) metastases.
Has multiple primary malignancies.
Has any history of interstitial lung disease (ILD)/pneumonitis irrespective of steroid use, or current ILD, or suspected ILD, or ILD that cannot be ruled out by imaging at screening
Has active or uncontrolled human immunodeficiency virus (HIV) infection.
Has active or uncontrolled hepatitis B virus (HBV)/hepatitis C virus (HCV) infection.
Any of the following within the past 6 months: cerebrovascular accident, transient ischemic attack, or other arterial thromboembolic event.
Current participation in other therapeutic investigational procedures, except for participation in long term survival follow-up (LTSFU) without any investigational treatment.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Los Angeles?

Yes, this clinical trial (NCT07739966) has an active research site in Los Angeles, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Solid Tumor Treatment Options in Los Angeles, CA

If you're searching for solid tumor treatment options in Los Angeles, CA, this clinical trial (NCT07739966) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Los Angeles research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced solid tumor specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all solid tumor clinical trials near you to find additional studies recruiting in your area.

More Advanced Solid Tumors Trials in Los Angeles, CA

See all advanced solid tumors clinical trials recruiting in Los Angeles — not just this study.

Browse Advanced Solid Tumors Trials in Los Angeles →

Browse More Trials by Condition

Advanced Solid Tumors TrialsAll Conditions →

Ready to Join in Los Angeles?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Los Angeles, CA